Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M77,888Revenue $M6,932Net Margin (%)26.9Z-Score16.5
Enterprise Value $M76,908EPS $7.8Operating Margin %36.3F-Score8
P/E(ttm))36.8Cash Flow Per Share $7.4Pre-tax Margin (%)35.8Higher ROA y-yY
Price/Book8.310-y EBITDA Growth Rate %25.7Quick Ratio1.7Cash flow > EarningsY
Price/Sales9.45-y EBITDA Growth Rate %20.1Current Ratio2.1Lower Leverage y-yY
Price/Cash Flow20.5y-y EBITDA Growth Rate %43.7ROA % (ttm)15.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)21.6Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M237ROI % (ttm)19.7Gross Margin Increase y-yN

Gurus Latest Trades with BIIB

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIIBGeorge Soros 2014-03-31 Buy 0.02%$273.518 - $351.94
($316.4)
$ 329.834%New holding, 7500 sh.7,500
BIIBJoel Greenblatt 2014-03-31 Buy 0.02%$273.518 - $351.94
($316.4)
$ 329.834%New holding, 3931 sh.3,931
BIIBRon Baron 2014-03-31 Buy 0.01%$273.518 - $351.94
($316.4)
$ 329.834%New holding, 6089 sh.6,089
BIIBJohn Burbank 2014-03-31 Buy 0.01%$273.518 - $351.94
($316.4)
$ 329.834%New holding, 783 sh.783
BIIBVanguard Health Care Fund 2014-03-31 Reduce-0.24%$273.518 - $351.94
($315.54)
$ 329.834%Reduce -32.19%599,400
BIIBRay Dalio 2014-03-31 Sold Out -0.04%$273.518 - $351.94
($316.4)
$ 329.834%Sold Out0
BIIBRay Dalio 2013-12-31 Add0.03%$223.85 - $295.88
($258.53)
$ 329.8328%Add 208.67%19,057
BIIBJohn Hussman 2013-12-31 Sold Out -0.99%$223.85 - $295.88
($258.53)
$ 329.8328%Sold Out0
BIIBVanguard Health Care Fund 2013-12-31 Reduce-0.47%$223.85 - $295.88
($258.53)
$ 329.8328%Reduce -39.09%884,000
BIIBJohn Hussman 2013-09-30 Add0.33%$206.53 - $248.13
($223.63)
$ 329.8348%Add 50%75,000
BIIBMario Gabelli 2013-09-30 Add$206.53 - $248.13
($223.63)
$ 329.8348%Add 81.87%3,310
BIIBRay Dalio 2013-09-30 Reduce-0.01%$206.53 - $248.13
($223.63)
$ 329.8348%Reduce -41.27%6,174
BIIBFrank Sands 2013-06-30 Add0.71%$192.77 - $240.86
($213.68)
$ 329.8354%Add 27.6%4,565,921
BIIBMario Gabelli 2013-06-30 Reduce$192.77 - $240.86
($213.68)
$ 329.8354%Reduce -25.1%1,820
BIIBJohn Hussman 2013-06-30 Reduce-1.45%$192.77 - $240.86
($213.68)
$ 329.8354%Reduce -80.62%50,000
BIIBPRIMECAP Management 2013-06-30 Reduce-0.28%$192.77 - $240.86
($213.68)
$ 329.8354%Reduce -5%18,246,809
BIIBRay Dalio 2013-06-30 Reduce-0.07%$192.77 - $240.86
($213.68)
$ 329.8354%Reduce -78.85%10,512
BIIBFrank Sands 2013-03-31 Buy 2.4%$142.82 - $192.618
($161.38)
$ 329.83104%New holding, 3578308 sh.3,578,308
BIIBRay Dalio 2013-03-31 Add0.06%$142.82 - $192.618
($161.38)
$ 329.83104%Add 172.25%49,712
BIIBJohn Hussman 2013-03-31 Reduce-0.92%$142.82 - $192.618
($161.38)
$ 329.83104%Reduce -48.4%258,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIIB is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BIIB Vanguard Health Care Fund 2014-06-30559,7000.240.47-6.62%
BIIB Ron Baron 2014-03-316,08900.01New Buy
BIIB George Soros 2014-03-317,50000.02New Buy
BIIB Joel Greenblatt 2014-03-313,93100.02New Buy
BIIB John Burbank 2014-03-3178300.01New Buy
BIIB Frank Sands 2014-03-314,873,0172.053.9+2.5%
BIIB PRIMECAP Management 2014-03-3117,502,1067.386.1-1.55%
BIIB Mario Gabelli 2014-03-313,58500.01-3.37%
BIIB Ray Dalio 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BIIB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SCANGOS GEORGE ACEO 2014-07-16Sell12,316$312.3710.29view
Posner Brian SDirector 2014-06-20Sell605$3159.37view
Posner Brian SDirector 2014-06-13Sell700$310.510.96view
SCANGOS GEORGE ACEO 2014-06-02Sell484$318.938.02view
Holtzman Steven HEVP Corporate Development 2014-05-19Sell1,221$289.1519.15view
SCANGOS GEORGE ACEO 2014-05-01Sell2,123$285.5620.65view
Holtzman Steven HEVP Corporate Development 2014-04-17Sell1,221$29118.39view
SCANGOS GEORGE ACEO 2014-04-01Sell2,123$308.4211.7view
PANGIA ROBERT WDirector 2014-04-01Sell6,250$308.4211.7view
Posner Brian SDirector 2014-03-31Sell3,000$296.7616.09view

Press Releases about BIIB :

Quarterly/Annual Reports about BIIB:

News about BIIB:

Articles On GuruFocus.com
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
Weekly 52-Week Highs Highlight: ORLY, LLL, BIIB, NVS Feb 09 2014 
Weekly CFO Sells Highlight: CSOD, UTX, MEMS, SBAC, BIIB Sep 22 2013 
PRIMECAP Trims Top Biotechs and More Aug 30 2013 
Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
52-Week High Guru Stocks: BIIB, GE, BDX, IR, PFE Sep 24 2012 
Weekly Top Insider Sells: GOOG, FIS, ORCL, and BIIB Aug 06 2012 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
Bearish John Hussman Sold Heavily in the First Quarter; New Portfolio Update May 02 2012 


More From Other Websites
BIOGEN IDEC INC. Financials Jul 30 2014
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues Jul 30 2014
Biogen Idec (BIIB) Highlighted As Momo Momentum Stock Jul 30 2014
Top Large-Cap Growth Funds Defy Group's Gravity Jul 29 2014
Biotech ETF Price Swings May Signal Need For Caution Jul 28 2014
The Zacks Analyst Blog Highlights: Verizon Communications, Apple, Biogen, Boeing and Caterpillar Jul 28 2014
Chipotle, Facebook Rally On Upside Earnings Surprise Jul 25 2014
AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus Jul 25 2014
UCB's Brivaracetam Positive in Phase III Epilepsy Study Jul 24 2014
What Makes Biogen Idec a Biotech Standout? Jul 24 2014
Video: Celgene, Alexion Earnings Top, But Stocks Fall Jul 24 2014
Gilead Sciences: Now Can We Call It a Value Stock? Jul 24 2014
The Zacks Analyst Blog Highlights: AbbVie, Shire, Amgen, InterMune and Biogen Jul 24 2014
Biogen Idec (BIIB) Soars: Stock Adds 11.2% in Session Jul 24 2014
Biogen price target raised to $387 from $343 at Citigroup Jul 24 2014
Aced the SAT? Try this Cramer question Jul 23 2014
Biogen, Gilead Earnings Crush Q2 Estimates Jul 23 2014
Biogen results crush consensus Jul 23 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide